Potential Role of Helicobacter Pylori Infection in Nonalcoholic Fatty Liver Disease

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2013 Nov 14

PMID 24222944

Citations 25

Authors

Meng Li

Zhe Shen

You-Ming Li

Affiliations

Soon will be listed here.

Abstract

Accumulating evidence has implicated Helicobacter pylori (H. pylori) infection in extragastrointestinal diseases, including obesity, type 2 diabetes mellitus, cardiovascular disease, and liver disease. Recently, there has been a special focus on H. pylori infection as a risk factor for the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is currently considered to be the most common liver disorder in western countries, and is rapidly becoming a serious threat to public health. The mechanisms of pathogenesis underlying NAFLD remain unclear at present and therapeutic options are limited. The growing awareness of the role of H. pylori in NAFLD is thus important to aid the development of novel intervention and prevention strategies, because the eradication of H. pylori is easy and much less expensive than long-term treatment of the other risk factors. H. pylori infection is involved in the pathogenesis of insulin resistance (IR), which is closely linked with NAFLD. It provides a new insight into the pathogenesis of NAFLD. This review probes the possible relationship between H. pylori and NAFLD, from the perspective of the potential mechanism of how H. pylori infection brings about IR and other aspects concerning this correlation.

Citing Articles

Impact of Helicobacter pylori Eradication on Clinical and Laboratory Parameters in Non-alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Jaber F, Alsakarneh S, Beran A, Alsharaeh T, Salahat A, Abdelshafi A Curr Med Sci. 2025; 45(1):1-10.

PMID: 39998769 DOI: 10.1007/s11596-025-00001-x.

Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience.

Gulati A, Roytman M, Lin J, McGrath M, Klar A, Boone K Surg Endosc. 2024; 38(11):6873-6879.

PMID: 39192041 DOI: 10.1007/s00464-024-11177-z.

Effect of Helicobacter Pylori Infection on Glucose Metabolism, Lipid Metabolism and Inflammatory Cytokines in Nonalcoholic Fatty Liver Disease Patients.

Xiao Q, Wang R, Wu H, Kuang W, Meng W, Cheng Z J Multidiscip Healthc. 2024; 17:1127-1135.

PMID: 38500481 PMC: 10946400. DOI: 10.2147/JMDH.S453429.

Impact of Infection on the Pathogenesis and Management of Nonalcoholic Fatty Liver Disease.

Mavilia-Scranton M, Wu G, Dharan M J Clin Transl Hepatol. 2023; 11(3):670-674.

PMID: 36969902 PMC: 10037521. DOI: 10.14218/JCTH.2022.00362.

Relationship of Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis.

Xu G, Ma S, Dong L, Mendez-Sanchez N, Li H, Qi X Can J Gastroenterol Hepatol. 2023; 2023:5521239.

PMID: 36742347 PMC: 9891807. DOI: 10.1155/2023/5521239.

References

Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J, Hui J, Fung C . NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35(2):373-9. DOI: 10.1053/jhep.2002.30692. View

Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S . Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med. 2012; 18(8):1279-85. DOI: 10.1038/nm.2851. View

Straubinger R, Greiter A, McDonough S, Gerold A, Scanziani E, Soldati S . Quantitative evaluation of inflammatory and immune responses in the early stages of chronic Helicobacter pylori infection. Infect Immun. 2003; 71(5):2693-703. PMC: 153233. DOI: 10.1128/IAI.71.5.2693-2703.2003. View

Basso D, Plebani M, Kusters J . Pathogenesis of Helicobacter pylori infection. Helicobacter. 2010; 15 Suppl 1:14-20. DOI: 10.1111/j.1523-5378.2010.00781.x. View

Arkan M, Hevener A, Greten F, Maeda S, Li Z, Long J . IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11(2):191-8. DOI: 10.1038/nm1185. View

Battles J, Williamson J, Pike K, Gorelick P, Ward J, Gonda M . Diagnostic assay for Helicobacter hepaticus based on nucleotide sequence of its 16S rRNA gene. J Clin Microbiol. 1995; 33(5):1344-7. PMC: 228160. DOI: 10.1128/jcm.33.5.1344-1347.1995. View

Tiniakos D, Vos M, Brunt E . Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5:145-71. DOI: 10.1146/annurev-pathol-121808-102132. View

Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere M . Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000; 23(1):57-63. DOI: 10.2337/diacare.23.1.57. View

Banatvala N, Mayo K, Megraud F, Jennings R, Deeks J, Feldman R . The cohort effect and Helicobacter pylori. J Infect Dis. 1993; 168(1):219-21. DOI: 10.1093/infdis/168.1.219. View

10.

Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka S, Takata H . Serum fetuin-A is an independent marker of insulin resistance in Japanese men. J Atheroscler Thromb. 2010; 17(9):925-33. DOI: 10.5551/jat.3830. View

11.

Cai D, Yuan M, Frantz D, Melendez P, Hansen L, Lee J . Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183-90. PMC: 1440292. DOI: 10.1038/nm1166. View

12.

Feinstein R, Kanety H, Papa M, Lunenfeld B, Karasik A . Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem. 1993; 268(35):26055-8. View

13.

Kashi M, Torres D, Harrison S . Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28(4):396-406. DOI: 10.1055/s-0028-1091984. View

14.

Hotamisligil G, Peraldi P, Budavari A, Ellis R, White M, Spiegelman B . IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271(5249):665-8. DOI: 10.1126/science.271.5249.665. View

15.

Larrain S, Rinella M . A myriad of pathways to NASH. Clin Liver Dis. 2012; 16(3):525-48. DOI: 10.1016/j.cld.2012.05.009. View

16.

Stern M . Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes. 1995; 44(4):369-74. DOI: 10.2337/diab.44.4.369. View

17.

Musso G, Gambino R, Cassader M . Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2008; 48(1):1-26. DOI: 10.1016/j.plipres.2008.08.001. View

18.

Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A . Extragastric manifestations of Helicobacter pylori infection. Helicobacter. 2010; 15 Suppl 1:60-8. DOI: 10.1111/j.1523-5378.2010.00778.x. View

19.

Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M . Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter. 2012; 17(6):444-51. DOI: 10.1111/j.1523-5378.2012.00970.x. View

20.

Akbas H, Basyigit S, Suleymanlar I, Kemaloglu D, Koc S, Davran F . The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. Lipids Health Dis. 2010; 9:92. PMC: 2936361. DOI: 10.1186/1476-511X-9-92. View